Skip to main content
Erschienen in: European Radiology 8/2011

01.08.2011 | Cardiac

Prognostic impact of T2-weighted CMR imaging for cardiac amyloidosis

verfasst von: Ralf Wassmuth, Hassan Abdel-Aty, Steffen Bohl, Jeanette Schulz-Menger

Erschienen in: European Radiology | Ausgabe 8/2011

Einloggen, um Zugang zu erhalten

Abstract

Objectives

Using cardiac magnetic resonance imaging (MRI) we tested the diagnostic value of various markers for amyloid infiltration.

Methods

We performed MRI at 1.5 T in 36 consecutive patients with cardiac amyloidosis and 48 healthy volunteers. The protocol included cine imaging, T2-weighted spin echo, T1-weighted spin echo before and early after contrast and late gadolinium enhancement. We compared the frequency of abnormalities and their relation to mortality.

Results

Median follow-up was 31 months. Twenty-three patients died. Mean left ventricular (LV) mass was 205 ± 70 g. LV ejection fraction (EF) was 55 ± 12%. T2 ratio was 1.5 ± 0.4. 33/36 patients had pericardial and 22/36 had pleural effusions. All but two had heterogeneous late enhancement. Surviving patients did not differ from those who had died with regard to gender, LV mass or volume. Surviving patients had a significantly higher LVEF (60.4 ± 9.9% vs. 51.6 ± 11.5%; p = 0.03). The deceased patients had a lower T2 ratio than those who survived (1.38 ± 0.42 vs. 1.76 ± 0.17; p = 0.005). Low T2 was associated with shorter survival (Chi-squared 11.3; p < 0.001). Cox regression analysis confirmed T2 ratio < 1.5 as the only independent predictors for survival.

Conclusion

Cardiac amyloidosis is associated with hypointense signal on T2-weighted images. A lower T2 ratio was independently associated with shortened survival.
Literatur
1.
Zurück zum Zitat Falk RH (2005) Diagnosis and management of the cardiac amyloidoses. Circulation 112:2047–2060PubMedCrossRef Falk RH (2005) Diagnosis and management of the cardiac amyloidoses. Circulation 112:2047–2060PubMedCrossRef
2.
Zurück zum Zitat Selvanayagam JB, Hawkins PN, Paul B, Myerson SG, Neubauer S (2007) Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol 50:2101–2110PubMedCrossRef Selvanayagam JB, Hawkins PN, Paul B, Myerson SG, Neubauer S (2007) Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol 50:2101–2110PubMedCrossRef
3.
Zurück zum Zitat Roberts WC, Waller BF (1983) Cardiac amyloidosis causing cardiac dysfunction: analysis of 54 necropsy patients. Am J Cardiol 52:137–146PubMedCrossRef Roberts WC, Waller BF (1983) Cardiac amyloidosis causing cardiac dysfunction: analysis of 54 necropsy patients. Am J Cardiol 52:137–146PubMedCrossRef
4.
Zurück zum Zitat Rahman JE, Helou EF, Gelzer-Bell R et al (2004) Noninvasive diagnosis of biopsy-proven cardiac amyloidosis. J Am Coll Cardiol 43:410–415PubMedCrossRef Rahman JE, Helou EF, Gelzer-Bell R et al (2004) Noninvasive diagnosis of biopsy-proven cardiac amyloidosis. J Am Coll Cardiol 43:410–415PubMedCrossRef
5.
Zurück zum Zitat Eriksson P, Backman C, Eriksson A, Eriksson S, Karp K, Olofsson BO (1987) Differentiation of cardiac amyloidosis and hypertrophic cardiomyopathy. A comparison of familial amyloidosis with polyneuropathy and hypertrophic cardiomyopathy by electrocardiography and echocardiography. Acta Med Scand 221:39–46PubMedCrossRef Eriksson P, Backman C, Eriksson A, Eriksson S, Karp K, Olofsson BO (1987) Differentiation of cardiac amyloidosis and hypertrophic cardiomyopathy. A comparison of familial amyloidosis with polyneuropathy and hypertrophic cardiomyopathy by electrocardiography and echocardiography. Acta Med Scand 221:39–46PubMedCrossRef
6.
Zurück zum Zitat Murtagh B, Hammill SC, Gertz MA, Kyle RA, Tajik AJ, Grogan M (2005) Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol 95:535–537PubMedCrossRef Murtagh B, Hammill SC, Gertz MA, Kyle RA, Tajik AJ, Grogan M (2005) Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol 95:535–537PubMedCrossRef
7.
Zurück zum Zitat Kristen AV, Meyer FJ, Perz JB et al (2005) Risk stratification in cardiac amyloidosis: Novel approaches. Transplantation 80:S151–S155PubMedCrossRef Kristen AV, Meyer FJ, Perz JB et al (2005) Risk stratification in cardiac amyloidosis: Novel approaches. Transplantation 80:S151–S155PubMedCrossRef
8.
Zurück zum Zitat Nordlinger M, Magnani B, Skinner M, Falk RH (2005) Is elevated plasma b-natriuretic peptide in amyloidosis simply a function of the presence of heart failure? Am J Cardiol 96:982–984PubMedCrossRef Nordlinger M, Magnani B, Skinner M, Falk RH (2005) Is elevated plasma b-natriuretic peptide in amyloidosis simply a function of the presence of heart failure? Am J Cardiol 96:982–984PubMedCrossRef
9.
Zurück zum Zitat Dispenzieri A, Gertz MA, Kyle RA et al (2004) Serum cardiac troponins and n-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 22:3751–3757PubMedCrossRef Dispenzieri A, Gertz MA, Kyle RA et al (2004) Serum cardiac troponins and n-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 22:3751–3757PubMedCrossRef
10.
Zurück zum Zitat Kim RJ, Shah DJ, Judd RM (2003) How we perform delayed enhancement imaging. J Cardiovasc Magn Reson 5:505–514PubMedCrossRef Kim RJ, Shah DJ, Judd RM (2003) How we perform delayed enhancement imaging. J Cardiovasc Magn Reson 5:505–514PubMedCrossRef
11.
Zurück zum Zitat Choudhury L, Mahrholdt H, Wagner A et al (2002) Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 40:2156–2164PubMedCrossRef Choudhury L, Mahrholdt H, Wagner A et al (2002) Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 40:2156–2164PubMedCrossRef
12.
Zurück zum Zitat Moon JC, Reed E, Sheppard MN et al (2004) The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 43:2260–2264PubMedCrossRef Moon JC, Reed E, Sheppard MN et al (2004) The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 43:2260–2264PubMedCrossRef
13.
Zurück zum Zitat Hunold P, Schlosser T, Vogt FM et al (2005) Myocardial late enhancement in contrast-enhanced cardiac MRI: Distinction between infarction scar and non-infarction-related disease. Am J Roentgenol 184:1420–1426 Hunold P, Schlosser T, Vogt FM et al (2005) Myocardial late enhancement in contrast-enhanced cardiac MRI: Distinction between infarction scar and non-infarction-related disease. Am J Roentgenol 184:1420–1426
14.
Zurück zum Zitat Lim RP, Srichai MB, Lee VS (2007) Non-ischemic causes of delayed myocardial hyperenhancement on MRI. Am J Roentgenol 188:1675–1681CrossRef Lim RP, Srichai MB, Lee VS (2007) Non-ischemic causes of delayed myocardial hyperenhancement on MRI. Am J Roentgenol 188:1675–1681CrossRef
15.
Zurück zum Zitat Bohl S, Wassmuth R, Abdel-Aty H et al (2008) Delayed enhancement cardiac magnetic resonance imaging reveals typical patterns of myocardial injury in patients with various forms of non-ischemic heart disease. Int J Cardiovasc Imaging 24:597–607PubMedCrossRef Bohl S, Wassmuth R, Abdel-Aty H et al (2008) Delayed enhancement cardiac magnetic resonance imaging reveals typical patterns of myocardial injury in patients with various forms of non-ischemic heart disease. Int J Cardiovasc Imaging 24:597–607PubMedCrossRef
16.
Zurück zum Zitat Maceira AM, Joshi J, Prasad SK et al (2005) Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 111:186–193PubMedCrossRef Maceira AM, Joshi J, Prasad SK et al (2005) Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 111:186–193PubMedCrossRef
17.
Zurück zum Zitat Perugini E, Rapezzi C, Piva T et al (2006) Noninvasive evaluation of the myocardial substrate of cardiac amyloidosis by gadolinium cardiac magnetic resonance. Heart 92(3):343–349PubMedCrossRef Perugini E, Rapezzi C, Piva T et al (2006) Noninvasive evaluation of the myocardial substrate of cardiac amyloidosis by gadolinium cardiac magnetic resonance. Heart 92(3):343–349PubMedCrossRef
18.
Zurück zum Zitat Vogelsberg H, Mahrholdt H, Deluigi CC et al (2008) Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: Noninvasive imaging compared to endomyocardial biopsy. J Am Coll Cardiol 51:1022–1030PubMedCrossRef Vogelsberg H, Mahrholdt H, Deluigi CC et al (2008) Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: Noninvasive imaging compared to endomyocardial biopsy. J Am Coll Cardiol 51:1022–1030PubMedCrossRef
19.
Zurück zum Zitat Seeger A, Klumpp B, Kramer U et al (2009) MRI assessment of cardiac amyloidosis: experience of six cases with review of the current literature. Br J Radiol 82:337–342PubMedCrossRef Seeger A, Klumpp B, Kramer U et al (2009) MRI assessment of cardiac amyloidosis: experience of six cases with review of the current literature. Br J Radiol 82:337–342PubMedCrossRef
20.
Zurück zum Zitat Abdel-Aty H, Boye P, Zagrosek A et al (2005) Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: comparison of different approaches. J Am Coll Cardiol 45:1815–1822PubMedCrossRef Abdel-Aty H, Boye P, Zagrosek A et al (2005) Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: comparison of different approaches. J Am Coll Cardiol 45:1815–1822PubMedCrossRef
21.
Zurück zum Zitat Friedrich MG, Strohm O, Schulz-Menger J, Marciniak H, Luft FC, Dietz R (1998) Contrast media-enhanced magnetic resonance imaging visualizes myocardial changes in the course of viral myocarditis. Circulation 97:1802–1809PubMed Friedrich MG, Strohm O, Schulz-Menger J, Marciniak H, Luft FC, Dietz R (1998) Contrast media-enhanced magnetic resonance imaging visualizes myocardial changes in the course of viral myocarditis. Circulation 97:1802–1809PubMed
22.
Zurück zum Zitat Anderson JL, Horne BD, Pennell DJ (2005) Atrial dimensions in health and left ventricular disease using cardiovascular magnetic resonance. J Cardiovasc Magn Reson 7:671–675PubMed Anderson JL, Horne BD, Pennell DJ (2005) Atrial dimensions in health and left ventricular disease using cardiovascular magnetic resonance. J Cardiovasc Magn Reson 7:671–675PubMed
23.
Zurück zum Zitat Maceira AM, Prasad SK, Khan M, Pennell DJ (2006) Normalized left ventricular systolic and diastolic function by steady state free precession cardiovascular magnetic resonance. J Cardiovasc Magn Reson 8:417–426PubMedCrossRef Maceira AM, Prasad SK, Khan M, Pennell DJ (2006) Normalized left ventricular systolic and diastolic function by steady state free precession cardiovascular magnetic resonance. J Cardiovasc Magn Reson 8:417–426PubMedCrossRef
24.
Zurück zum Zitat Gean-Marton AD, Kirsch CF, Vezina LG, Weber AL (1991) Focal amyloidosis of the head and neck: evaluation with CT and MR imaging. Radiology 181:521–525PubMed Gean-Marton AD, Kirsch CF, Vezina LG, Weber AL (1991) Focal amyloidosis of the head and neck: evaluation with CT and MR imaging. Radiology 181:521–525PubMed
25.
Zurück zum Zitat Celletti F, Fattori R, Napoli G et al (1999) Assessment of restrictive cardiomyopathy of amyloid or idiopathic etiology by magnetic resonance imaging. Am J Cardiol 83(798–801):a10 Celletti F, Fattori R, Napoli G et al (1999) Assessment of restrictive cardiomyopathy of amyloid or idiopathic etiology by magnetic resonance imaging. Am J Cardiol 83(798–801):a10
26.
Zurück zum Zitat Barnes ME, Miyasaka Y, Seward JB et al (2004) Left atrial volume in the prediction of first ischemic stroke in an elderly cohort without atrial fibrillation. Mayo Clin Proc 79:1008–1014PubMedCrossRef Barnes ME, Miyasaka Y, Seward JB et al (2004) Left atrial volume in the prediction of first ischemic stroke in an elderly cohort without atrial fibrillation. Mayo Clin Proc 79:1008–1014PubMedCrossRef
27.
Zurück zum Zitat Fattori R, Rocchi G, Celletti F, Bertaccini P, Rapezzi C, Gavelli G (1998) Contribution of magnetic resonance imaging in the differential diagnosis of cardiac amyloidosis and symmetric hypertrophic cardiomyopathy. Am Heart J 136:824–830PubMedCrossRef Fattori R, Rocchi G, Celletti F, Bertaccini P, Rapezzi C, Gavelli G (1998) Contribution of magnetic resonance imaging in the differential diagnosis of cardiac amyloidosis and symmetric hypertrophic cardiomyopathy. Am Heart J 136:824–830PubMedCrossRef
28.
29.
Zurück zum Zitat Asaumi J, Yanagi Y, Hisatomi M, Konouchi H, Kishi K (2001) CT and MR imaging of localized amyloidosis. Eur J Radiol 39:83–87PubMedCrossRef Asaumi J, Yanagi Y, Hisatomi M, Konouchi H, Kishi K (2001) CT and MR imaging of localized amyloidosis. Eur J Radiol 39:83–87PubMedCrossRef
30.
Zurück zum Zitat Sueyoshi E, Sakamoto I, Okimoto T, Hayashi K, Tanaka K, Toda G (2006) Cardiac amyloidosis: typical imaging findings and diffuse myocardial damage demonstrated by delayed contrast-enhanced MRI. Cardiovasc Intervent Radiol 29:710–712PubMedCrossRef Sueyoshi E, Sakamoto I, Okimoto T, Hayashi K, Tanaka K, Toda G (2006) Cardiac amyloidosis: typical imaging findings and diffuse myocardial damage demonstrated by delayed contrast-enhanced MRI. Cardiovasc Intervent Radiol 29:710–712PubMedCrossRef
31.
Zurück zum Zitat vanden Driesen RI, Slaughter RE, Strugnell WE (2006) MR findings in cardiac amyloidosis. AJR Am J Roentgenol 186:1682–1685CrossRef vanden Driesen RI, Slaughter RE, Strugnell WE (2006) MR findings in cardiac amyloidosis. AJR Am J Roentgenol 186:1682–1685CrossRef
32.
Zurück zum Zitat Bucciarelli-Ducci C, Locca D, Barbeau G, Prasad SK (2007) Value of cardiovascular magnetic resonance for determining cardiac involvement in systemic amyloidosis. Eur Heart J 28:1186PubMedCrossRef Bucciarelli-Ducci C, Locca D, Barbeau G, Prasad SK (2007) Value of cardiovascular magnetic resonance for determining cardiac involvement in systemic amyloidosis. Eur Heart J 28:1186PubMedCrossRef
33.
Zurück zum Zitat Syed IS, Glockner JF, Feng D et al (2010) Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging 3:155–164PubMedCrossRef Syed IS, Glockner JF, Feng D et al (2010) Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging 3:155–164PubMedCrossRef
34.
Zurück zum Zitat Leeson CP, Myerson SG, Walls GB, Neubauer S, Ormerod OJ (2006) Atrial pathology in cardiac amyloidosis: evidence from ECG and cardiovascular magnetic resonance. Eur Heart J 27:1670PubMedCrossRef Leeson CP, Myerson SG, Walls GB, Neubauer S, Ormerod OJ (2006) Atrial pathology in cardiac amyloidosis: evidence from ECG and cardiovascular magnetic resonance. Eur Heart J 27:1670PubMedCrossRef
35.
Zurück zum Zitat Van Geluwe F, Dymarkowski S, Crevits I, De Wever W, Bogaert J (2006) Amyloidosis of the heart and respiratory system. Eur Radiol 16:2358–2365PubMedCrossRef Van Geluwe F, Dymarkowski S, Crevits I, De Wever W, Bogaert J (2006) Amyloidosis of the heart and respiratory system. Eur Radiol 16:2358–2365PubMedCrossRef
36.
Zurück zum Zitat Cheng AS, Banning AP, Mitchell AR, Neubauer S, Selvanayagam JB (2006) Cardiac changes in systemic amyloidosis: visualisation by magnetic resonance imaging. Int J Cardiol 113:E21–E23PubMedCrossRef Cheng AS, Banning AP, Mitchell AR, Neubauer S, Selvanayagam JB (2006) Cardiac changes in systemic amyloidosis: visualisation by magnetic resonance imaging. Int J Cardiol 113:E21–E23PubMedCrossRef
37.
Zurück zum Zitat Ruberg FL, Appelbaum E, Davidoff R et al (2009) Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in light-chain cardiac amyloidosis. Am J Cardiol 103:544–549PubMedCrossRef Ruberg FL, Appelbaum E, Davidoff R et al (2009) Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in light-chain cardiac amyloidosis. Am J Cardiol 103:544–549PubMedCrossRef
38.
Zurück zum Zitat Austin BA, Tang WH, Rodriguez ER et al (2009) Delayed hyper-enhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis. JACC Cardiovasc Imaging 2:1369–1377PubMedCrossRef Austin BA, Tang WH, Rodriguez ER et al (2009) Delayed hyper-enhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis. JACC Cardiovasc Imaging 2:1369–1377PubMedCrossRef
39.
Zurück zum Zitat Lyne JC, Petryka J, Pennell DJ (2008) Atrial enhancement by cardiovascular magnetic resonance in cardiac amyloidosis. Eur Heart J 29:212PubMedCrossRef Lyne JC, Petryka J, Pennell DJ (2008) Atrial enhancement by cardiovascular magnetic resonance in cardiac amyloidosis. Eur Heart J 29:212PubMedCrossRef
40.
Zurück zum Zitat Gertz MA, Comenzo R, Falk RH et al (2005) Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (al): a consensus opinion from the 10th international symposium on amyloid and amyloidosis, Tours, France, 18–22 April 2004. Am J Hematol 79:319–328PubMedCrossRef Gertz MA, Comenzo R, Falk RH et al (2005) Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (al): a consensus opinion from the 10th international symposium on amyloid and amyloidosis, Tours, France, 18–22 April 2004. Am J Hematol 79:319–328PubMedCrossRef
41.
Zurück zum Zitat Maceira AM, Prasad SK, Hawkins PN, Roughton M, Pennell DJ (2008) Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis. J Cardiovasc Magn Reson 10:54PubMedCrossRef Maceira AM, Prasad SK, Hawkins PN, Roughton M, Pennell DJ (2008) Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis. J Cardiovasc Magn Reson 10:54PubMedCrossRef
42.
Zurück zum Zitat Sparrow P, Amirabadi A, Sussman MS, Paul N, Merchant N (2009) Quantitative assessment of myocardial T2 relaxation times in cardiac amyloidosis. J Magn Reson Imaging 30:942–946PubMedCrossRef Sparrow P, Amirabadi A, Sussman MS, Paul N, Merchant N (2009) Quantitative assessment of myocardial T2 relaxation times in cardiac amyloidosis. J Magn Reson Imaging 30:942–946PubMedCrossRef
43.
Zurück zum Zitat Krombach GA, Hahn C, Tomars M et al (2007) Cardiac amyloidosis: MR imaging findings and T1 quantification, comparison with control subjects. J Magn Reson Imaging 25:1283–1287PubMedCrossRef Krombach GA, Hahn C, Tomars M et al (2007) Cardiac amyloidosis: MR imaging findings and T1 quantification, comparison with control subjects. J Magn Reson Imaging 25:1283–1287PubMedCrossRef
44.
Zurück zum Zitat Hosch W, Bock M, Libicher M et al (2007) MR-relaxometry of myocardial tissue: significant elevation of T1 and T2 relaxation times in cardiac amyloidosis. Invest Radiol 42:636–642PubMedCrossRef Hosch W, Bock M, Libicher M et al (2007) MR-relaxometry of myocardial tissue: significant elevation of T1 and T2 relaxation times in cardiac amyloidosis. Invest Radiol 42:636–642PubMedCrossRef
Metadaten
Titel
Prognostic impact of T2-weighted CMR imaging for cardiac amyloidosis
verfasst von
Ralf Wassmuth
Hassan Abdel-Aty
Steffen Bohl
Jeanette Schulz-Menger
Publikationsdatum
01.08.2011
Verlag
Springer-Verlag
Erschienen in
European Radiology / Ausgabe 8/2011
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-011-2109-3

Weitere Artikel der Ausgabe 8/2011

European Radiology 8/2011 Zur Ausgabe

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.